VERUのチャート
VERUの企業情報
| symbol | VERU |
|---|---|
| 会社名 | Veru Inc （ベル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 一般消費財（Consumer Products） |
| 概要 | 事業概要 ヴェル(Veru Inc)（旧名：The Female Health Company）は男性・女性の健康・腫瘍学の医薬品とデバイスの開発・商業化に従事する治療会社である。同社は消費者向けのヘルスケア製品の開発、製造と販売に従事する。同社は医薬品・デバイス、消費者向けの健康製品及び公共部門という３つの事業区分により構成される。男性製品には良性前立腺肥大、男性不妊症、ホルモン性前立腺癌治療の副作用改善、前立腺癌、痛風と性機能不全の分野の候補製品を含む。女性製品には女性の性的健康、乳癌と卵巣癌向けの候補製品を含む。同社は「FC2」女性用コンドームを製造、販売、販売する。。「FC2」はヒト免疫不全ウイルスまたは後天性免疫不全症候群（HIV/ AIDS）を含む性感染症（STI）と望まない妊娠に対する二重保護を提供する。 ベルは米国のヘルスケア製品メ―カ―。女性と男性の健康に焦点を当て、主に女性用避妊具を製造・販売する。同社製品は女性用使い捨て避妊具｢FC2｣、ベンゾカインを含む男性用早漏予防ワイプ｢PREBOOST｣など。また、グロ―バル公衆衛生部門では、望まない妊娠と伝染病予防に焦点を当てる。本社所在地はフロリダ州マイアミ。 Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, VERU-100, and Zuclomiphene citrate. VERU-111 is an oral, first-in-class, new chemical entity that targets, crosslinks, and disrupts alpha and beta tubulin subunits of microtubules for the treatment of metastatic castration and androgen receptor resistant prostate cancer. VERU-100 is a novel, proprietary peptide formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT in men with advanced prostate cancer. The Veru breast cancer pipeline includes enobosarm for AR+/ER+/HER2- metastatic breast cancer and VERU-111 for taxane resistant metastatic triple negative breast cancer. Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor agonist that targets and activates the androgen receptor in AR+/ER+/HER2- metastatic breast cancer without unwanted masculinizing side effects. VERU-111 is also being advanced into a Phase 3 trial for the treatment of hospitalized patients with COVID-19 who are at high risk for acute respiratory distress syndrome. |
| 本社所在地 | 4400 Biscayne Boulevard Suite 888 Miami FL 33137 USA |
| 代表者氏名 | Elgar Peerschke エルガー・ピアースキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 312-595-9123 |
| 設立年月日 | 1896年 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 175人 |
| url | www.veruhealthcare.com |
| nasdaq_url | https://www.nasdaq.com/symbol/veru |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -18.49085 |
| 終値（lastsale） | 1.4 |
| 時価総額（marketcap） | 77398938.4 |
| 時価総額 | 時価総額（百万ドル） 84.16669 |
| 売上高 | 売上高（百万ドル） 14.35362 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 89.80956 |
| 当期純利益 | 当期純利益（百万ドル） -20.68567 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 30 June 2018 Veru Inc revenues increased 7% to $10.7M. Net loss before extraordinary items increased from $3.9M to $16M. Revenues reflect Other Countries segment increase from $843K to $3.5M United States segment increase from $358K to $2.6M. Higher net loss reflects Foreign currency transaction loss increase from $41K to $118K (expense). |
VERUのテクニカル分析
VERUのニュース
Veru Announces Presentation of Phase 3 Study of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 11th International Conference on Emerging Infectious Diseases (ICEID) on August 7-1 2022/08/09 12:30:00 Wallstreet:Online
MIAMI, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Phase 3 COVID-19 study results of Sabizabulin for the Treatment of Hospitalized COVID-19 Patients at High Risk for Acute Respiratory
Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer 2022/08/03 19:16:24 Seeking Alpha
Oppenheimer said that a new analysis conducted by Veru (VERU) on mortality rates in a phase 3 trial of its COVID-19 therapy sabizabulin assuages concerns and will lead to an EUA.
Oppenheime on Veru, Inc. : ''We believe this update will provide comfort'' 2022/08/03 18:48:02 Investing.com
https://www.investing.com/news/pro/oppenheime-on-veru-inc--we-believe-this-update-will-provide-comfort-432SI-2862362
Can you still get a good price for Veru Inc. (VERU) Shares at this point? 2022/08/02 18:40:00 US Post News
The share price of Veru Inc. (NASDAQ:VERU) fell to $11.87 per share on Monday from $12.10. While Veru Inc. has underperformed by -1.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERU rose by 72.78%, with highs and lows ranging from $18.40 to $4.34, whereas the […]
Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think 2022/07/29 15:00:00 Stocks Register
Veru Inc. (NASDAQ:VERU) price on Thursday, July 28, fall -3.10% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.21. A look at the stock’s price movement, the close in the last trading session was $12.60, moving within a range at $12.03 and $12.7447. The beta value (5-Year … Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think Read More »
Can you still get a good price for Veru Inc. (VERU) Shares at this point? 2022/08/02 18:40:00 US Post News
The share price of Veru Inc. (NASDAQ:VERU) fell to $11.87 per share on Monday from $12.10. While Veru Inc. has underperformed by -1.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, VERU rose by 72.78%, with highs and lows ranging from $18.40 to $4.34, whereas the […]
Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think 2022/07/29 15:00:00 Stocks Register
Veru Inc. (NASDAQ:VERU) price on Thursday, July 28, fall -3.10% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $12.21. A look at the stock’s price movement, the close in the last trading session was $12.60, moving within a range at $12.03 and $12.7447. The beta value (5-Year … Veru Inc.’s (VERU) Stock Is Harder To Predict Than You Think Read More »
Veru Inc. (NASDAQ: VERU) Has Succeeded In Generating Interest In 2022, The Stock Is Up 113.92% Year-To-Date 2022/07/28 15:30:00 Marketing Sentinel
Veru Inc. (NASDAQ:VERU)’s traded shares stood at 6.48 million during the last session, with the company’s beta value hitting -0.30. At the close of trading, the stock’s price was $12.60, to imply an increase of 2.02% or $0.25 in intraday trading. The VERU share’s 52-week high remains $18.40, putting it -46.03% down since that peak … Veru Inc. (NASDAQ: VERU) Has Succeeded In Generating Interest In 2022, The Stock Is Up 113.92% Year-To-Date Read More »
Veru to Report Fiscal 2022 Third Quarter Financial Results, Host Conference Call on August 11th 2022/07/28 12:30:00 GlobeNewswire
MIAMI, July 28, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that it will report financial results for its fiscal 2022 third quarter, on Thursday, August 11, 2022, before the market opens. Veru’s management will host a conference call that same day at 8 a.m. ET to review the Company’s performance and to answer questions. The call will also be accessible via webcast.
VERU stock gains as U.K. supports expedited review for COVID-19 therapy 2022/07/25 12:05:39 Seeking Alpha
Clinical-stage biotech Veru (VERU) announced on Monday that U.K
Veru Stock Could Face Difficulties If the Culper Research Report Is True 2022/05/09 13:30:42 InvestorPlace
Veru (NASDAQ: VERU ) is set to discuss on May 10 with the Food and Drug Administration a pre-Emergency Use Authorization (EUA) meeting for its Phase 3 Covid-19 drug, sabizabulin (VERU-111). That could potentially be a turning point for Veru stock. However, the only problem is that there is a research report dated May 2 from a short-seller firm, Culper Research. The allegations the firm makes are of a nature that most potential investors in Veru stock are likely to read. To put bluntly the research report implies that Veru’s Phase 3 study is not likely to succeed in helping VERU-111 obtain a EUA. The report points out two major issues: first, the Phase 3 Covid-19 study contains “glaring issues, compounded by management misrepresentations.” For example, on April 11 Veru announced its Covid-19 drug brought down the mortality rate by 55% but the Culper report said that this was a manipulation of how high mortality rates were with Covid-19. Also, apparently, most of the patients in the study were outside of the U.S.
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru''s Pre-EUA Meeting, Conference Presentations And More 2022/05/09 12:33:09 Benzinga
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve''s 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB ), considered a proxy for the sector, shed close to 3 percent during the week. Penny stock and digital therapeutics company Better Therapeutics, Inc. (NASDAQ: BTTX ) more than doubled despite a lack of any meaningful catalysts. On the other hand, Connect Biopharma Holdings Limited (NASDAQ: CNTB ) lost more than half its market value after its investigational asset that is being evaluated for ulcerative colitis flunked a mid-stage trial. Earnings news flow also continued to move stocks in the space. Here are the key catalysts for biotech stocks in the unfolding week: Conferences World Federation of Hemophilia, or WFH, 2022 World Congress: May 8-11, in Montreal, Canada, as well as virtually BofA Securities 2022 Healthcare Conference: May 9–13, in Las Vegas, Nevada Psych Symposium: May 11, in London, U.K.
Why Veru Stock Plummeted on Monday 2022/05/02 21:33:48 The Motley Fool
A short-seller makes some worrying accusations against the company.
Veru Whale Trades Spotted 2022/05/02 20:07:01 Benzinga
A whale with a lot of money to spend has taken a noticeably bearish stance on Veru . Looking at options history for Veru (NASDAQ: VERU ) we detected 21 strange trades. If we consider the specifics of each trade, it is accurate to state that 42% of the investors opened trades with bullish expectations and 57% with bearish. From the overall spotted trades, 4 are puts, for a total amount of $184,800 and 17, calls, for a total amount of $776,914. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $17.5 for Veru … Full story available on Benzinga.com